期刊文献+

外用人纤维蛋白原的分离纯化 被引量:5

Isolation and purification of fibrinogen from external use
下载PDF
导出
摘要 目的:建立一种外用人纤维蛋白原的制备工艺。方法:以血浆冷沉淀为原料,利用铝胶吸附、酸沉淀、离子交换层析、低温乙醇沉淀等方法提取人纤维蛋白原。参考中国药典方法检测外用人纤维蛋白原的复溶时间、凝固活力、纯度、人凝血因子XⅢ效价等主要指标。结果:本研究制备的产品具有复溶时间短、凝固活力强、纯度高等优点,产品质量明显高于国家标准,优于市场上同类产品。结论:本研究建立的外用人纤维蛋白原的制备工艺,能有效提高血浆的综合利用率,具有极高的经济价值和社会价值。 Objective: A new method for preparation of human fibrinogen from external use was established. Methods: The process to cryprecipitate as raw material,using alumina adsorption,acid precipitation,ion exchange chromatography,low temperature ethanol precipitation method to extract human fibrinogen. Reference the method of Chinese pharmacopoeia,the detecting fibrinogen from external use of the main indicators of dissolution time,coagulation activity,purity,human coagulation factor XⅢ titer. Results: The products prepared in this study have the advantages of short dissolution time,strong solidification activity,high purity,and the product quality is higher than the national standard,and better than the similar products in the market.Conclusion: This study established the preparation of human fibrinogen,and can effectively improve the comprehensive utilization of plasma,with a high economic value and social value.
出处 《临床医药实践》 2015年第12期923-925,共3页 Proceeding of Clinical Medicine
基金 江西省重点新产品计划项目(项目编号:20132CX28100)
关键词 人纤维蛋白原 冷沉淀 离子交换层析 fibrinogen cryoprecipitate ion exchange chromatography
  • 引文网络
  • 相关文献

参考文献5

二级参考文献34

  • 1章金刚.生物技术产品的病毒安全性[J].中国医药生物技术,2007,2(2):81-84. 被引量:7
  • 2王春仁,王召旭,宋谊萍,彭新杰,奚廷斐.医用纤维蛋白胶亚急性毒性实验研究[J].中国药事,2007,21(7):472-475. 被引量:9
  • 3[1]Dickneite G,Metzner H,Kroez M,et al.The importance of factor ⅩⅢ as a component of fibrin sealants[J].J Surg Res,2002,107:186-195.
  • 4[2]Kaetsu H,Uchida T,Shinya N.Increased effectiveness of fibrin sealant with a higher fibrin concentration[J].Int J Adhesion Adhesives,2000,20(1):27-31.
  • 5[3]Jackson MR,New and potential uses of fibrin sealants as an adjunct to surgical hemostasis[J].Am J Surg,2001,182:36S-39S.
  • 6[6]Velada JL,Hollingsbee DA,Menzies AR.Reproducibility of the mechanical properties of Vivo stat system patient-derived fibrin sealant[J].Biomaterials,2002,23:2249-2254.
  • 7[7]Dickneite G,Metzner H,Nicolay U.Prevention of suture hole bleeding using fibrin sealant:benefits of factor ⅩⅢ[J].J SurgRes,2000,93:201-205.
  • 8[8]Spotnitz WD.Commercial fibrin sealants in surgical care[J].Am J Surg,2001,182:8S-14S.
  • 9[9]Jackson MR.Fibrin sealants in surgical practice:an overview[J].Am J Surg 2001,182:1S-7S.
  • 10[10]Kawamura M,Sawafuji M,Watanabe M,et al.Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery[J].Ann Thorac Surg 2002,73:1098-1100.

共引文献28

同被引文献46

引证文献5

二级引证文献19

;
使用帮助 返回顶部